Litronesib is primarily investigated for its potential applications in cancer treatment, particularly as a kinesin spindle protein (KSP) inhibitor. By targeting KSP, it disrupts the formation of the mitotic spindle, which is essential for cell division. This mechanism makes it a promising candidate for halting the proliferation of cancer cells, especially in tumors that are resistant to conventional therapies. Research focuses on its use in treating solid tumors and hematologic malignancies, with ongoing clinical trials evaluating its efficacy and safety in combination with other anticancer agents. Its ability to selectively target cancer cells while sparing normal cells could offer a more effective and less toxic treatment option.